An extension of the Benefit Risk Assessment of VaccinEs (BRAVE) Toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union
View ORCID ProfileNeilshan Loedy, Hector G Dorta, Steven Abrams, Jonas Crèvecoeur, Daniel R. Morales, Catherine Cohet, Lander Willem, Geert Molenberghs, Niel Hens, Xavier Kurz, Chantal Quinten, Johan Verbeeck
doi: https://doi.org/10.1101/2024.08.09.24311669
Neilshan Loedy
1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
Hector G Dorta
2European Medicines Agency, Amsterdam, The Netherlands
Steven Abrams
1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
3Global Health Institute (GHI), Family Medicine and Population Health, University of Antwerp, Antwerp, Belgium
Jonas Crèvecoeur
1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
Daniel R. Morales
2European Medicines Agency, Amsterdam, The Netherlands
Catherine Cohet
2European Medicines Agency, Amsterdam, The Netherlands
Lander Willem
4Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium
5Primary and interdisciplinary care (ELIZA), Family Medicine and Population Health, University of Antwerp, Antwerp, Belgium
Geert Molenberghs
1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
6I-Biostat, KU Leuven, Leuven, Belgium
Niel Hens
1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
4Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium
Xavier Kurz
2European Medicines Agency, Amsterdam, The Netherlands
Chantal Quinten
2European Medicines Agency, Amsterdam, The Netherlands
Johan Verbeeck
1Data Science Institute, I-Biostat, Hasselt University, Diepenbeek, Belgium
Article usage
Posted August 09, 2024.
An extension of the Benefit Risk Assessment of VaccinEs (BRAVE) Toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union
Neilshan Loedy, Hector G Dorta, Steven Abrams, Jonas Crèvecoeur, Daniel R. Morales, Catherine Cohet, Lander Willem, Geert Molenberghs, Niel Hens, Xavier Kurz, Chantal Quinten, Johan Verbeeck
medRxiv 2024.08.09.24311669; doi: https://doi.org/10.1101/2024.08.09.24311669
An extension of the Benefit Risk Assessment of VaccinEs (BRAVE) Toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union
Neilshan Loedy, Hector G Dorta, Steven Abrams, Jonas Crèvecoeur, Daniel R. Morales, Catherine Cohet, Lander Willem, Geert Molenberghs, Niel Hens, Xavier Kurz, Chantal Quinten, Johan Verbeeck
medRxiv 2024.08.09.24311669; doi: https://doi.org/10.1101/2024.08.09.24311669
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (714)
- Anesthesia (209)
- Cardiovascular Medicine (2986)
- Dermatology (254)
- Emergency Medicine (446)
- Epidemiology (12847)
- Forensic Medicine (12)
- Gastroenterology (839)
- Genetic and Genomic Medicine (4652)
- Geriatric Medicine (428)
- Health Economics (735)
- Health Informatics (2960)
- Health Policy (1076)
- Hematology (394)
- HIV/AIDS (938)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (478)
- Neurology (4441)
- Nursing (239)
- Nutrition (653)
- Oncology (2310)
- Ophthalmology (655)
- Orthopedics (260)
- Otolaryngology (328)
- Pain Medicine (285)
- Palliative Medicine (85)
- Pathology (504)
- Pediatrics (1205)
- Primary Care Research (506)
- Public and Global Health (7039)
- Radiology and Imaging (1557)
- Respiratory Medicine (927)
- Rheumatology (447)
- Sports Medicine (387)
- Surgery (494)
- Toxicology (60)
- Transplantation (213)
- Urology (186)